Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Palvella TherapeuticsPVLA | Open-market sale10b5-1 plan | 06/17 | 06/22 | 4,302 sh3 trades | $110.73avg. | $476,369.12 | −100.0% | |
Palvella TherapeuticsPVLA | Open-market sale10b5-1 plan | 05/20 | 05/22 | 4,302 sh3 trades | $110.56avg. | $475,646.55 | −100.0% | |
Palvella TherapeuticsPVLA | Open-market sale10b5-1 plan | 04/15 | 04/17 | 4,302 sh5 trades | $127.24avg. | $547,396.58 | −100.0% | |
George M. JenkinsDirector | Palvella TherapeuticsPVLA | Open-market buy | 03/30 | 04/01 | 445 sh | $112.30 | $49,973.5 | +0.2% |
Palvella TherapeuticsPVLA | Open-market sale10b5-1 plan | 03/18 | 03/20 | 4,302 sh3 trades | $117.99avg. | $507,606.5 | −100.0% | |
Elaine J. HeronDirector | Palvella TherapeuticsPVLA | Open-market buy | 02/27 | 03/02 | 2,400 sh | $125.00 | $300,000 | +5.3% |
George M. JenkinsDirector | Palvella TherapeuticsPVLA | Open-market buy | 02/27 | 03/02 | 4,000 sh | $125.00 | $500,000 | +2.2% |
Palvella TherapeuticsPVLA | Open-market sale10b5-1 plan | 02/18 | 02/20 | 4,302 sh2 trades | $79.40avg. | $341,579.88 | −100.0% | |
Palvella TherapeuticsPVLA | Open-market sale10b5-1 plan | 01/21 | 01/23 | 4,302 sh2 trades | $97.63avg. | $419,983.03 | −100.0% | |
Palvella TherapeuticsPVLA | Open-market sale10b5-1 plan | 25/12/17 | 25/12/19 | 4,302 sh | $96.47 | $415,013.94 | −100.0% | |
Palvella TherapeuticsPVLA | Open-market sale10b5-1 plan | 25/11/19 | 25/11/21 | 4,302 sh2 trades | $86.23avg. | $370,981.02 | −100.0% | |
Palvella TherapeuticsPVLA | Open-market buy | 25/04/09 | 25/04/10 | 4,990 sh2 trades | $20.20avg. | $100,797.3 | No record | |
George M. JenkinsDirector | Palvella TherapeuticsPVLA | Open-market buy | 24/12/18 | 24/12/19 | 4,000 sh | $12.93 | $51,720 | +2.3% |